

Françoise Picarel-Blanchot

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1548370/publications.pdf>

Version: 2024-02-01

7
papers

521
citations

1477746

6
h-index

1719596

7
g-index

7
all docs

7
docs citations

7
times ranked

397
citing authors

| # | ARTICLE | IF | CITATIONS |
|---|--|-----|-----------|
| 1 | Efficacy of the Novel Antidepressant Agomelatine on the Circadian Rest-Activity Cycle and Depressive and Anxiety Symptoms in Patients With Major Depressive Disorder. <i>Journal of Clinical Psychiatry</i> , 2010, 71, 109-120. | 1.1 | 218 |
| 2 | Efficacy of the novel antidepressant agomelatine for anxiety symptoms in major depression. <i>Human Psychopharmacology</i> , 2013, 28, 151-159. | 0.7 | 207 |
| 3 | Sustained efficacy of agomelatine 10 mg, 25 mg, and 25-50 mg on depressive symptoms and functional outcomes in patients with major depressive disorder. A placebo-controlled study over 6 months. <i>European Neuropsychopharmacology</i> , 2016, 26, 378-389. | 0.3 | 36 |
| 4 | A pooled analysis of six month comparative efficacy and tolerability in four randomized clinical trials: agomelatine versus escitalopram, fluoxetine, and sertraline. <i>CNS Spectrums</i> , 2013, 18, 163-170. | 0.7 | 35 |
| 5 | Agomelatine in Standard Medical Practice in Depressed Patients: Results of a 1-Year Multicentre Observational Study In France. <i>Clinical Drug Investigation</i> , 2020, 40, 1009-1020. | 1.1 | 12 |
| 6 | Efficacy of Agomelatine 25-50mg for the Treatment of Anxious Symptoms and Functional Impairment in Generalized Anxiety Disorder: A Meta-Analysis of Three Placebo-Controlled Studies. <i>Advances in Therapy</i> , 2021, 38, 1567-1583. | 1.3 | 11 |
| 7 | Relative short-term efficacy and acceptability of agomelatine versus vortioxetine in adult patients suffering from major depressive disorder. <i>Human Psychopharmacology</i> , 2018, 33, e2646. | 0.7 | 2 |